Dicerna Announces Fourth Quarter and Full Year 2015 Financial and Operational Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/24/2026
- S&P 500 ends marginally lower as investors focus on US-Iran war
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oil gains on little sign of progress in US-Iran talks
- S&P 500 history shows strong gains across Fed hiking cycles: BCA
- JPMorgan upgrades CoreWeave on stronger compute pricing
- Plug Power COO resigns to join another company
- Bloom Energy falls as Oracle invokes force majeure on AI project
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oracle Sends Force Majeure Notice Over New Mexico Data Center - Bloomberg
- Akamai signs $11.6B deal with Anthropic, up to $20B potential
Jefferies Reiterates Buy on Dicerna Pharma (DRNA) Following 4Q - PT to $19
March 11, 2016 9:38 AM ESTJefferies maintained a Buy rating on Dicerna Pharmaceuticals (NASDAQ: DRNA), and cut the price target to $19.00 (from $25.00), following the company's 4Q. DRNA reported a Narrower 4Q15 net loss of $15.7M, compared to Jefferies' net loss estimate of $18.1M.
Analyst Eun Yang... More
Dicerna Pharma (DRNA) Tops Q4 EPS by 8c
March 10, 2016 4:10 PM ESTDicerna Pharma (NASDAQ: DRNA) reported Q4 EPS of ($0.76), $0.08 better than the analyst estimate of ($0.84).
For earnings history and earnings-related data on Dicerna Pharma (DRNA) click here.
... More